Revance Releases Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Revance Therapeutics (RVNC) Misses Q3 EPS by 8c
November 2, 2017 4:53 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.01), $0.08 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50 thousand.
2017 Financial Outlook
Revance reaffirmed its financial guidance provided in January 2017. Revance expects cash... More
